OraSure In-Home HIV Test’s Promise Outweighs Risks, Panel Concludes
This article was originally published in The Gray Sheet
Executive Summary
FDA’s Blood Products Advisory Committee endorses OraSure’s OraQuick in-home HIV test in a unanimous 17-0 vote on May 15. If approved, OraQuick would be the first-ever over-the-counter test for HIV that can be performed entirely in the home by untrained users.
You may also be interested in...
OraSure Preps October Launch Of First-Ever In-Home HIV Test
Firm gains PMA approval for OraQuick July 3, making it the first available HIV test that can be performed entirely in the home by untrained users.
News In Brief
LabCorp buys Medtox Scientific. Halma buys SunTech. FCC outlines wireless health plan. More briefs.
OraSure Over-The-Counter HIV Test: Complete PMA Filing Planned By Year End
OraSure Technologies expects to complete a PMA filing for its OraQuick Advance rapid HIV-1 and -2 over-the-counter saliva test by the end of the year.